reports
- Peter Thilo Hasler
Vidac Pharma gets clinical trial authorization
Vidac Pharma recently announced that the European Medicines Agency (EMA) has granted approval for the company’s first clinical study specifically designed to address highly proliferative actinic keratoses (AK). The upcoming Phase 2 trial is structured to evaluate safety, tolerability, and preliminary efficacy signals of Vidac Pharma’s investigational therapy in patients presenting with advanced AK lesions. The study protocol incorporates rigorously defined inclusion and exclusion criteria, clini...
- Peter Thilo Hasler
Recent study confirms Vidac Pharma’s innovative approach
A new scientific paper provides robust preclinical evidence that mitochondrial transplantation can be an effective strategy to increase the responsiveness of tumour cells to established chemotherapeutic agents in lower doses, thus significantly reducing their side effects. It also contributes significantly to the understanding of the role of mitochondria in tumour biology and opens up new perspectives for combinatorial therapy concepts, strongly confirming the Vidac Pharma approach, which is alr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.